GlassScriptPhysician profile
Khalid Mahmood
NPI 1114910361
$5,746.19
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $1,142 · 2021: $1,893 · 2022: $1,348 · 2023: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $615.08 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $549.73 | 2019-2021 | |
| Biogen, INC. | $435.66 | 2020-2023 | Tysabri, Vumerity |
| Acadia Pharmaceuticals INC | $388.84 | 2019-2023 | Nuplazid |
| Abbvie INC. | $317.18 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $297.87 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $290.00 | 2019-2022 | |
| Sk Life Science, INC. | $266.15 | 2020-2023 | Xcopri |
| Ucb, INC. | $253.38 | 2019-2022 | |
| Emd Serono, INC. | $192.38 | 2020-2022 | |
| Lundbeck LLC | $125.51 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $123.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $120.27 | 2019-2022 | |
| Lilly USA, LLC | $116.36 | 2020-2023 | Reyvow, Emgality |
| Eisai INC. | $109.90 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.